Lista de obras - Simona Colla - Dominio Público Uruguay

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

artículo científico publicado en 2006

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

artículo científico publicado en 2015

Angiogenic switch in multiple myeloma.

artículo científico publicado en 2004

Angiopoietin-1 and myeloma-induced angiogenesis.

artículo científico publicado en 2005

Angiopoietins expression by human myeloma cells

artículo científico publicado en 2003

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

artículo científico publicado en 2010

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

artículo científico publicado en 2008

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point

artículo científico publicado en 2015

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

artículo científico publicado en 2008

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

artículo científico publicado en 2015

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

artículo científico publicado en 2009

Do human myeloma cells directly produce basic FGF?

artículo científico publicado en 2003

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

artículo científico publicado en 2004

Down-regulation of EZH2 expression in myelodysplastic syndromes

artículo científico publicado en 2016

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

artículo científico publicado en 2004

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion

artículo científico publicado en 2015

Dysfunctional telomeres and hematological disorders.

artículo científico publicado en 2018

Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells

artículo científico publicado en 1999

Erratum: Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer

artículo científico publicado en 2015

Erratum: Telomere dysfunction induces metabolic and mitochondrial compromise

scholarly article published in Nature

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

artículo científico publicado en 2015

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

artículo científico publicado en 2010

Hematologic Malignancies With Extramedullary Spread of Disease

artículo científico publicado en 2003

Hematopoiesis under telomere attrition at the single-cell resolution

artículo científico publicado en 2021

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

artículo científico publicado en 2005

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

artículo científico publicado en 2002

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

artículo científico publicado en 2013

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

artículo científico publicado en 2017

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

artículo científico publicado en 2017

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

artículo científico publicado en 2018

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients

artículo científico publicado en 2006

KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

artículo científico publicado en 2018

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells

artículo científico publicado en 2005

Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells

artículo científico publicado en 2010

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

artículo científico publicado en 2010

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

artículo científico publicado en 2005

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

artículo científico publicado en 2012

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

artículo científico publicado en 2004

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

artículo científico publicado en 2014

PAF promotes stemness and radioresistance of glioma stem cells.

artículo científico publicado en 2017

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.

artículo científico publicado en 2016

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network

artículo científico

Passenger deletions generate therapeutic vulnerabilities in cancer

artículo científico publicado en 2012

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

artículo científico

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

artículo científico publicado en 2003

RNA processing: a new player of genomic instability in multiple myeloma.

artículo científico publicado en 2017

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

artículo científico publicado en 2022

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

artículo científico publicado en 2017

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

artículo científico publicado en 2015

Telomere dysfunction induces metabolic and mitochondrial compromise.

artículo científico publicado en 2011

The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2004

The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation

scientific article published on 31 May 2019

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angio

artículo científico publicado en 2007

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

artículo científico publicado en 2010

Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis

artículo científico publicado en 2000

Update on the pathogenesis of osteolysis in multiple myeloma patients

artículo científico publicado en 2004

e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?

artículo científico publicado en 2004

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. ⬇️

artículo científico publicado en 2012

Lista de obras de Simona Colla

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Angiogenic switch in multiple myeloma.

Angiopoietin-1 and myeloma-induced angiogenesis.

Angiopoietins expression by human myeloma cells

Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients

CC-chemokine ligand 20/macrophage inflammatory protein-3α and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions.

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point

Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.

Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.

Do human myeloma cells directly produce basic FGF?

Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?

Down-regulation of EZH2 expression in myelodysplastic syndromes

Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis.

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion

Dysfunctional telomeres and hematological disorders.

Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells

Erratum: Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer

Erratum: Telomere dysfunction induces metabolic and mitochondrial compromise

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.

Hematologic Malignancies With Extramedullary Spread of Disease

Hematopoiesis under telomere attrition at the single-cell resolution

Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients

Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.

ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients

KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells

Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.

New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

PAF promotes stemness and radioresistance of glioma stem cells.

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network

Passenger deletions generate therapeutic vulnerabilities in cancer

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis

RNA processing: a new player of genomic instability in multiple myeloma.

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

Telomere dysfunction induces metabolic and mitochondrial compromise.

The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment

The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angio

The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.

Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis

Update on the pathogenesis of osteolysis in multiple myeloma patients

e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. ⬇️

mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy